Events Press Releases Investor Home Investor Resources Corporate Presentation> Stock Information> SEC Filings> Analyst Coverage> Investor FAQ> Corporate Governance> Committee> IR Home> Crinetics Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome Dec 18, 2023 at 5:00 PM EST Join Webcast Supporting Materials Ph2 Carcinoid Syndrome_Final.pdf 1.1 MB Email Alerts RSS Feeds Print Email Page Events Press Releases Investor Home Contact Press Releases & Events> Financial Alerts> Media Inquiries> Contact IR> Required fields denoted by an asterisk (). Alert type Quote SEC Filing Weekly Summary Email Leave this field blank First Name Last Name Email Organization Message Leave this field blank Contact Press Releases & Events> Financial Alerts> Required fields denoted by an asterisk (). Alert type Quote SEC Filing Weekly Summary Email Leave this field blank Media Inquiries> Contact IR> First Name Last Name Email Organization Message Leave this field blank
Crinetics Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome Dec 18, 2023 at 5:00 PM EST Join Webcast Supporting Materials Ph2 Carcinoid Syndrome_Final.pdf 1.1 MB
